Oxford BioMedica of the UK has linked up with the USA's renowned Mayo Clinic to develop a novel gene therapy for the treatment of chronic glaucoma…The pact builds on earlier pre-clinical research, conducted by Mayo Clinic which has established initial proof-of-concept for this approach to treating chronic glaucoma.

PharmaTimes, Kevin Grogan, 11/1/11

Additional coverage: Pharmaceutical Business Review, Genetic Engineering News

Tags: Business Relations, Ophthalmology